Deramiocel for Duchenne: HOPE-3 Results and the FDA Decision Due November 22, 2026

Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on reports from NeurologyLive, Parent Project Muscular Dystrophy and Capricor Therapeutics (see sources below).

Deramiocel, developed by Capricor Therapeutics, is an experimental cell therapy for Duchenne muscular dystrophy that has had a very bumpy road with the US regulator. It was rejected once in 2025, resubmitted after a phase 3 trial called HOPE-3, reviewed by an expert panel that voted against it in July 2026, and is now waiting for a final FDA decision on November 22, 2026. At the 2026 World Muscle Society Congress, the company also shared new 24-month data. This article explains, in simple words, what deramiocel is, what the trial found, why the experts were divided, and what it means for families in Pakistan. For Duchenne basics, read our guide: Duchenne Muscular Dystrophy (DMD): Symptoms, Causes, Life Expectancy and Treatment.

Quick facts

• Deramiocel is made of donor heart-derived cells (allogeneic cardiosphere-derived cells), given by intravenous infusion every three months.
• The HOPE-3 trial enrolled 106 boys and young men, mostly non-walking, with a mean age of about 15.
• It met its main goal of slowing the loss of upper limb function (54% slower decline), and a key heart goal (91% slower decline in heart pumping measured by MRI).
• An FDA advisory committee voted 9 to 3 against recommending approval on July 29, 2026.
• The FDA's final decision date was extended to November 22, 2026. The outcome is not known.
• To our knowledge, it is not available in Pakistan.

What Is Deramiocel?

Deramiocel is a cell therapy. It is made of cells grown from donated heart tissue. These cells do not become new muscle. Instead, they are thought to release substances that reduce inflammation and scarring and support injured heart and skeletal muscle. Unlike gene therapy and exon-skipping medicines, it is not designed for a specific gene change, so in principle it could suit many people with Duchenne, including those who can no longer walk. It is an investigational therapy and is not approved anywhere at the time of writing.

What Did the HOPE-3 Trial Find?

HOPE-3 was a randomised, double-blind, placebo-controlled phase 3 trial, the strongest kind of study design. It was published in The Lancet in July 2026. Boys and young men received either 150 million cells or a placebo into a vein every three months for a year. More than three-quarters had a diagnosis of heart muscle disease (cardiomyopathy), and about 90% were already on heart medicines.

Goal	Result with deramiocel	Statistical result
Main goal: upper limb function (PUL v2.0)	54% slower decline than placebo	P = .029
Key secondary goal: heart pumping (LVEF on cardiac MRI)	91% slower decline than placebo	P = .041

The most common side effects were allergic-type (hypersensitivity) reactions, which the team managed with steroid and antihistamine pretreatment. No unexpected safety signals were reported in the longer follow-up of the earlier HOPE-2 group.

New Data from the 2026 World Muscle Society Congress

At the congress in Hiroshima, Capricor presented 24-month results from the open-label extension of HOPE-3, in which everyone could receive deramiocel. According to the company, the boys who started deramiocel after a year on placebo showed a significantly slower decline in upper limb function than during their placebo year, and both groups declined more slowly than expected from natural history over two years. These data were included in the FDA review as an amendment. Open-label data, in which everyone knows they are receiving the treatment, are less strong than the randomised comparison.

Why Did the Experts Disagree?

• History: The FDA first accepted the application in 2025, then issued a complete response letter in July 2025 citing insufficient evidence of effectiveness and unresolved manufacturing questions. After HOPE-3, the company resubmitted.
• The July 29, 2026 panel vote: The FDA's advisory committee voted 9 to 3 against recommending approval. Reviewers questioned changes made to the statistical analysis plan after randomisation, doubted that heart pumping measured by MRI is a proven stand-in for real clinical benefit, and noted a signal of increased left ventricular volume that needs a closer look.
• The other side: The company and patient advocates argued that the totality of evidence, especially the upper limb data, together with the lack of alternatives for older, non-walking patients, supports approval.
• A panel vote is advice, not a decision. The FDA can approve, ask for more data or reject.

What Happens Next?

After the panel, Capricor sent the FDA more data and asked it to consider a narrower proposed use: preserving upper limb function. The FDA accepted this as a major amendment, and moved the decision date from August 22 to November 22, 2026. The extension does not say whether the application will be approved or what population or label would be allowed. We could not find a published price for deramiocel.

What It Means for Families in Pakistan

• Not available yet: It is not approved anywhere, and it is not available in Pakistan. Even if the FDA approves it, importing a new cell therapy would need DRAP permission, a specialised centre and cold-chain handling.
• Why it matters: Many Pakistani boys with Duchenne are diagnosed late and reach the non-walking stage with heart involvement. A therapy aimed at the arms and heart in older patients addresses a real gap.
• Cost: Because it is given every three months, the cost over a year could be high. Please do not pay anyone for "stem cell" or cell therapies offered in Pakistan or abroad that are not part of an approved or registered clinical trial.
• Basic care: Heart checks, heart medicines, steroids as advised, breathing care and vaccines remain the foundation for every boy.

What Families Can Do Now

1. Ask your neurologist and cardiologist about regular heart checks, including heart MRI where available.
2. Keep a genetic report and all medical records in one file.
3. Follow the FDA decision on November 22, 2026, and talk to your specialist about what it would mean for you.
4. Avoid unregulated "stem cell" clinics.
5. Register with MDP so that families of older and non-walking patients are counted too.

Muscular Dystrophy Pakistan Every patient counts. Register with MDP. Patients and families living with muscular dystrophy and other neuromuscular disorders can register on the MDP patient registration portal. Your registration helps us understand the real picture and speak up for timely diagnosis, care and support. ✔ Simple online registration ✔ For patients and families ✔ Helps make every patient visible Register Now → musculardystrophypk.org/registration

Frequently Asked Questions

Is deramiocel approved?

No. It is under FDA review, with a decision date of November 22, 2026.

Who could use it?

The trial studied mostly older, non-walking boys and young men with Duchenne, many with heart muscle disease. The company has proposed a narrower use centred on preserving upper limb function. The final label, if any, is up to the FDA.

Does it work for every gene change?

It is not designed around a specific gene change, so in principle it is not limited by the type of DMD mutation.

Is it a gene therapy?

No. It is a cell therapy, made of donor heart-derived cells, and it does not change the patient's genes.

Is it available in Pakistan?

No, not to our knowledge.

Waiting for a Decision, Caring in the Meantime

The coming weeks may bring an important decision for older boys and young men with Duchenne, for whom there are few options. Whatever the FDA decides, the basics do not change: early diagnosis, heart and breathing care, honest information and a community that stands together. Follow the MDP blog for our update after the decision.

Sources and Further Reading

• NeurologyLive, FDA extends deramiocel review for Duchenne muscular dystrophy after HOPE-3 amendment
• Parent Project Muscular Dystrophy, Catch up on the 31st Congress of the World Muscle Society
• Capricor Therapeutics, HOPE-3 open-label extension data on upper limb function
• Capricor Therapeutics, Extension of PDUFA target action date
• McDonald CM et al. Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, July 2026.

Medical disclaimer: This article is for awareness and education only. It is not a substitute for professional medical advice, diagnosis or treatment. Regulatory status can change, so please check the latest news and consult your specialist. Never start, change or stop a medicine without your doctor's advice.